R
R.H.W. Lorijn
Researcher at Amgen
Publications - 3
Citations - 61
R.H.W. Lorijn is an academic researcher from Amgen. The author has contributed to research in topics: Clinical trial & Clinical endpoint. The author has an hindex of 3, co-authored 3 publications receiving 59 citations.
Papers
More filters
Journal ArticleDOI
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part one: rationale and hypothesis.
Wilfried Lorenz,Benno Stinner,Artur Bauhofer,Matthias Rothmund,Ilhan Celik,A. Fingerhut,Michael Koller,R.H.W. Lorijn,P.O. Nyström,Helmut Sitter,Moshe Schein,Joseph S. Solomkin,Hans Troidl,Jeremy C Wyatt,Dietmar H. Wittmann +14 more
TL;DR: This study design differs from other trials on preoperative prophylaxis and postoperative recovery, and has been developed to try a new concept and avoid previous failures.
Journal ArticleDOI
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4) : Part one
Wilfried Lorenz,Benno Stinner,Artur Bauhofer,Matthias Rothmund,Ilhan Celik,A. Fingerhut,Michael Koller,R.H.W. Lorijn,P.O. Nyström,Helmut Sitter,Moshe Schein,Joseph S. Solomkin,Hans Troidl,Jeremy C Wyatt,Dietmar H. Wittmann +14 more
TL;DR: The following hypothesis will be tested in patients with operations for colorectal cancer and increased preoperative risk (ASA 3 and 4): is the outcome as evaluated by the hermeneutic endpoint (quality of life expressed by the patient) and mechanistic endpoints improved in the group receiving filgrastim prophylaxis in comparison with the placebo group?
Journal ArticleDOI
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part three: individual patient, complication algorithm and quality manage.
Benno Stinner,Artur Bauhofer,Wilfried Lorenz,Matthias Rothmund,U. Plaul,Alexander Torossian,Ilhan Celik,Helmut Sitter,Michael Koller,A. Black,Dan G. Duda,Albrecht Encke,B. Greger,H. van Goor,E. Hanisch,R. Hesterberg,Klaus-Jochen Klose,F. Lacaine,R.H.W. Lorijn,C. Margolis,E. Neugebauer,P.O. Nyström,P.H.M. Reemst,Moshe Schein,J. Solovera +24 more
TL;DR: This new type of a single-centre trial aims to reduce the gap between animal experiments and clinical trials or - if it fails - at least demonstrates new ways for explaining the failures.